ORIC Pharmaceuticals, Inc. (ORIC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.4200 |
| Open | 3.4400 |
| Bid | 3.3300 x 1100 |
| Ask | 3.3700 x 1000 |
| Day's Range | 3.1400 - 3.4550 |
| 52 Week Range | 2.6200 - 26.7000 |
| Volume | |
| Avg. Volume | 700,088 |
| Market Cap | 132.717M |
| Beta (5Y Monthly) | 2.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3050 |
| Earnings Date | Mar 21, 2022 - Mar 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- GlobeNewswire
ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Dominic Piscitelli, chief financial officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7:00 a.m. ET. The pre-recorded presentation will be available through the investor s
- Identity and Access Management & Cybersecurity Provider BIO-key to Participate in H.C. Wainwright Global Investment Conference, CEO Presentation Available Starting Tue., May 24GlobeNewswire
- Looking Glass Labs Presenting at the HC Wainwright Conference Being Held in Miami from May 23-26, 2022CNW Group
- Simply Wall St.
Jacob Chacko Is The President of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) And They Just Picked Up 128% More Shares
Those following along with ORIC Pharmaceuticals, Inc. ( NASDAQ:ORIC ) will no doubt be intrigued by the recent purchase...
- GlobeNewswire
ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented three preclinical poster presentations and one preclinical oral presentation at the 2022 American Cancer Research Association (AACR) Annual Meeting. “Our four presentations at AACR reflect the broad and diverse pipeline of differentiated programs at O
